CClinicalTrials.gg
CompletedNCT06191003Updated Jan 5, 2024

Urdu Version of Maastricht Upper Extremity Questionnaire Reliability Validity Study.

An observational study in Carpal Tunnel Syndrome, sponsored by Riphah International University. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Riphah International University · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
135
Ages
18 Years to 50 Years
Sex
All
01

Study summary

In this study, the examiners will investigate the reliability and validity of Mastrict Upper Extremity scale in Urdu language in Pakistani patients with Carpal tunnel syndrome.

Read the detailed description

The objective of this study is to translate as well as culturally adapt the Mastrict Upper Extrimity scale (MUEQ) into Urdu language and to test its reliability and validity in patients with Carpal Tunnel Syndrome. This cross-sectional survey will use convenience sampling technique to enroll the participants on a pre-defined criteria.

The outcomes of this study will help in finding the reliability and validity of MUEQ in patients with CTS. The reliability of this scale will be examined using internal consistency and test-retest methods. The internal consistency will be checked by Cronbach's alpha value. The test-retest reliability will be analyzed using an interclass correlation with patients.

02

Conditions studied

  • Carpal Tunnel Syndrome
03

In context

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 139 are open to participants now.

This study's enrollment of 135 is above the median of 90 across 127 observational studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pakistani computer user's population with complaint of arm, neck, shoulder (CANS) was included in this study.

Inclusion criteria

  • Individuals who had to execute computer jobs in office.
  • Individuals who have been working in present position for minimum 6 months
  • Individuals who have been working for at least 4 hours or more in a day

Exclusion criteria

Exclusion Criteria:

  • Individuals who had Severe phsycytric and behavioral complaint
  • Individuals who had prior injury of upper extremity
  • Individuals who had any surgery of upper extremity
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
135 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Visual Analouge scale

    The visual analogue scale is a simple and frequently used method for the assessment of variations in intensity of pain. In clinical practice the percentage of pain relief, assessed by Visual Analouge scale, is often considered as a measure of the efficacy of treatment.

    Time frame: 12th week

  2. JAMAR Hydraulic hand Dynamometer

    Hand grip strength is an indicator of general muscle strength that is measured using a hand dynamometer.

    Time frame: 12th week

  3. Boston questionnaire

    The Boston Carpal Tunnel Score is a patient-reported questionnaire that examines symptom severity and overall functional status of patients with carpal tunnel syndrome.

    Time frame: 12th week

07

Study locations

1 site
  • Riphah International University
    Faisalabad, Punjab 38000, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191003
Lead sponsor
Riphah International University
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
May 1, 2021
Primary completion
Apr 28, 2023
Completion
Apr 28, 2023
Last update
Jan 5, 2024

Study contacts

Muhammad Kashif
study chair · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion